Clovis Oncology to File sNDA for Rubraca in BRCA1/2-Mutant Prostate Cancer
The drug improved progression-free survival in the Phase III TRITON3 trial in patients with BRCA1/2-mutant metastatic castration-resistant prostate cancer.
Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response
Researchers showed that a novel radiotracer dubbed [18F]FTT could reach target cancer cells in metastatic and primary tumors in patients eligible for PARP inhibitor therapy.
During a call to discuss Q2 financials, the company reported a 13 percent year-over-year decrease in Rubraca revenues and said it is exploring strategies to raise additional capital.
EMA's CHMP Recommends Restricting Third-Line Ovarian Cancer Indication for Clovis' Rubraca
The committee said the indication in BRCA1/2-mutated ovarian cancer patients should be removed from the PARP inhibitor label based on negative confirmatory trial data.
Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients
After seeing patients with co-occurring biomarkers fail on a PARP inhibitor, but respond to checkpoint inhibitors, researchers are studying this further in larger cohorts.